Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Inova Decides to End PGx Test Offerings in Response to FDA Warning Letter

Inova Decides to End PGx Test Offerings in Response to FDA Warning Letter

Apr 15, 2019
|
staff reporter

This article has been updated with a statement from the Clinical Pharmacogenetics Implementation Consortium.

NEW YORK (GenomeWeb) – Inova Health System has decided to completely stop performing its suite of pharmacogenetic tests in response to a US Food and Drug Administration warning letter.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

What's Popular?

In Regulatory News & FDA Approvals

  1. PerkinElmer Preliminary Q1 Revenues Grow 98 Percent; FDA Issues EUA for PCR COVID-19 Test

  2. Australian Firm AnteoTech Obtains CE Marking for COVID-19 Antigen Test, Reader

  3. Thermo Fisher Scientific Gets FDA EUA for High-Throughput, Automated COVID-19 Test Kit

  4. Siemens Healthineers Gets CE Mark for Point-of-Care High-Sensitivity Cardiac Troponin I Test

  5. Ortho Clinical Diagnostics Gets Additional CE Mark for Coronavirus Antigen Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.